Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (macimorelin) for Diagnosing Adult Growth Hormone Deficiency TORONTO, ONTARIO, May 25, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...

Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin CHARLESTON, S.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary, (“Aeterna” or the “Company”), a specialty biopharmaceutical...